The single-arm, multicentre, open-label, dose expansion Phase I clinical trial would aim to evaluate the safety and efficacy of LBL-034 in patients with r/r multiple myeloma who have received prior treatment. Image Credit: Nemes Laszlo / Shutterstock.
Nanjing Leads Biolabs chief medical officer Dr Charles Cai said in a press release: “LBL-034 adopts a unique molecular design, which enables the drug to specifically bind to GPRC5D-expressing tumourGPRC5D-expressing tumour cells with high affinity and reduces the risk of non-specific activation of T-cells, thereby enhancing anti-tumour efficacy and reducing the potential risk of immunotoxicity.”
“LBL-034 demonstrated robust anti-tumour activities and good safety profile in pre-clinical studies.”
The single-arm, multicentre, open-label, dose-expansion Phase I clinical trial would aim to evaluate the safety and efficacy of LBL-034 in patients with R/R multiple myeloma who have received prior treatment. The additional aim of the first-in-human study is to determine the Phase II recommended dose.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.